SCHEMBL2285452

SCHEMBL2285452

F[B-](F)(F)F.NC(=O)c1ccccc1CCF

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
FOLH1 Q04609 1/20 0.42
METAP2 P50579 1/20 0.41
ADRB2 P07550 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HMGB1 P09429 1/20 0.39
AURKA O14965 1/20 0.37
RPS6KB1 P23443 1/20 0.37
SIRT2 Q8IXJ6 1/20 0.37
GAA P10253 1/20 0.37
CTNNB1 P35222 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7874452 0.96 ALDH1A1 (0.47) BCAT2ALDH1A1KDM4EMAPTHPGD
SCHEMBL30839543 0.85 ALDH1A1 (0.44) BCAT2ALDH1A1KDM4EMAPTHPGD
SCHEMBL4735612 0.84 ALDH1A1 (0.54) BCAT2ALDH1A1KDM4EMAPTHPGD
SCHEMBL731621 0.82 HMGB1 (0.55) BCAT2ALDH1A1KDM4EMAPTHPGD
Hydrochloric Acid SCHEMBL4422370 0.81 HMGB1 (0.53) BCAT2ALDH1A1KDM4EMAPTHPGD
SCHEMBL3828592 0.80 KDM4E (0.50) BCAT2ALDH1A1KDM4EMAPTHPGD
SCHEMBL30177551 0.80 ALDH1A1 (0.50) BCAT2ALDH1A1KDM4EMAPTHPGD
SCHEMBL3262902 0.79 ALDH1A1 (0.45) BCAT2ALDH1A1KDM4EMAPTHPGD
SCHEMBL363595 0.79 BCAT2 (0.48) BCAT2ALDH1A1KDM4EMAPTHPGD
SCHEMBL31721455 0.79 FOLH1 (0.66) ALDH1A1KDM4EMAPTHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8212049-B2 Electronically tuned ligands for asymmetric hydrogenation BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-03 US disclosed
US-20110257393-A1 Electronically Tuned Ligands For Asymmetric Hydrogenation BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-20 US disclosed
US-7994335-B2 Electronically tuned ligands for asymmetric hydrogenation BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-09 US disclosed
US-20100041898-A1 Electronically Tuned Ligands For Asymmetric Hydrogenation BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 US disclosed
WO-2008067218-A1 ELECTRONICALLY TUNED LIGANDS FOR ASYMMETRIC HYDROGENATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-06-05 WO disclosed
EP-1218388-B1 ELECTRONICALLY TUNED LIGANDS BOEHRINGER INGELHEIM PHARMA (US) 2004-01-28 EP disclosed
EP-1218388-A1 ELECTRONICALLY TUNED LIGANDS Boehringer Ingelheim Pharmaceuticals, Inc. (US) 2002-07-03 EP disclosed
US-6316620-B1 AS LIGANDS TO TRANSITION METALS WHICH ARE USED AS CATALYSTS IN SYNTHESIZING ASYMMETRIC COMPOUNDS TO OBTAIN SPECIFIC ENANTIOMERS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2001-11-13 US disclosed
WO-2001018012-A1 ELECTRONICALLY TUNED LIGANDS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041898-A1 Electronically Tuned Ligands For Asymmetric Hydrogenation BID, HDHD5, HRH4 BCAT2 2576/4885ALDH1A1 2836/4885KDM4E 4189/4885
US-20110257393-A1 Electronically Tuned Ligands For Asymmetric Hydrogenation BID, HDHD5, HRH4 BCAT2 2576/4885ALDH1A1 2836/4885KDM4E 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.